Relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer patients
1. Progression-free and overall survival were greater in relacorilant plus nab-paclitaxel compared to nab-paclitaxel alone. 2. The rate of adverse ...
Tag: chemotherapy
#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]
Imfinzi Combo Shows Promise in Early Gastric Cancer At the American Society of Clinical Oncology meeting earlier this week, investigators ...
Sotorasib plus panitumumab may be a promising treatment option for colorectal cancer
1. While not statistically significant, the use of sotorasib plus panitumumab may have a 30% relative risk reduction in the ...
Durvalumab and bevacizumab plus chemoembolization improves progression-free survival in hepatocellular carcinoma
1. Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events ...
Perioperative chemotherapy improves survival in esophageal cancer
1. Among patients with resectable esophageal cancer, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in improved survival ...
Transarterial chemoembolization with pembrolizumab and levatinib improves survival in unresectable hepatocellular carcinoma
1. Progression-free survival was significantly greater in the lenvatinib plus pembrolizumab group compared to placebo. 2. Overall survival was higher ...
#VisualAbstract: Adjuvant Atezolizumab Does Not Provide Benefit in Early Triple-Negative Breast Cancer
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Perioperative Chemotherapy is Superior to Preoperative Chemoradiotherapy in Esophageal Cancer
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Neoadjuvant Nivolumab/Ipilimumab Vs Chemotherapy in Resectable NSCLC
1. Median event-free survival was 54.8 months with immunotherapy vs 20.9 months with chemotherapy, with HR 0.77 (non-significant). 2. Grade ...
